Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG40033)
Regulator Name | CircST6GALNAC6 (circRNA) | ||||
---|---|---|---|---|---|
Synonyms |
CircST6GALNAC6
Click to Show/Hide
|
||||
Gene Name | CircST6GALNAC6 | ||||
Regulator Type | circRNA |
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
CircST6GALNAC6
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Heat shock protein beta-1 (HSPB1) [Suppressor; Marker]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Target for Ferroptosis | Marker/Suppressor | |||
Responsed Disease | Bladder cancer | ICD-11: 2C94 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
UM-UC-3 cells | Bladder carcinoma | Homo sapiens | CVCL_1783 |
J82 cells | Bladder carcinoma | Homo sapiens | CVCL_0359 | |
Response regulation | CircST6GALNAC6 inhibits HSPB1 and promotes cell ferroptosis by occupying the phosphorylation site (Ser-15) of HSBP1 and activating the P38 MAPK signaling pathway. Therefore, enhancing the expression of circST6GALNAC6 to promote ferroptosis or using circST6GALNAC6 as a biomarker of ferroptosis sensitivity is of considerable importance to the development and application of ferroptosis intervention methods in bladder cancer. | |||
Bladder cancer [ICD-11: 2C94]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | CircST6GALNAC6 (circRNA) | circRNA | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model |
UM-UC-3 cells | Bladder carcinoma | Homo sapiens | CVCL_1783 |
J82 cells | Bladder carcinoma | Homo sapiens | CVCL_0359 | |
Response regulation | CircST6GALNAC6 inhibits HSPB1 and promotes cell ferroptosis by occupying the phosphorylation site (Ser-15) of HSBP1 and activating the P38 MAPK signaling pathway. Therefore, enhancing the expression of circST6GALNAC6 to promote ferroptosis or using circST6GALNAC6 as a biomarker of ferroptosis sensitivity is of considerable importance to the development and application of ferroptosis intervention methods in bladder cancer. | |||